Subscribe: Merck.com - Corporate News
http://www.merck.com/rss/corporate.xml
Added By: Feedage Forager Feedage Grade B rated
Language: English
Tags:
dateline city  exchange nyse  kenilworth  language english  merck  mrk  msd united  nyse  states canada  ticker  united states 
Rate this Feed
Rate this feedRate this feedRate this feedRate this feedRate this feed
Rate this feed 1 starRate this feed 2 starRate this feed 3 starRate this feed 4 starRate this feed 5 star

Comments (0)

Feed Details and Statistics Feed Statistics
Preview: Merck.com - Corporate News

Corporate News





 



America’s Diabetes Challenge Unveils Common Challenges Affecting the Type 2 Diabetes Community

Tue, 25 Apr 2017 12:00:16 +0000

Dateline City:
KENILWORTH, N.J.

Merck, the American Diabetes Association and Celebrity Voices Offer Tips to Help People Tackle Their Obstacles Head On

KENILWORTH, N.J. – Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the American Diabetes Association today revealed common challenges affecting the millions of Americans living with type 2 diabetes as part of the program America’s Diabetes Challenge: Get to Your Goals. Last year, award-winning artist Tim McGraw, renowned actress S. Epatha Merkerson and Chef Leticia Moreinos Schwartz called on patients and their loved ones to share their stories – from inspirational successes to daily struggles.

Language:
English

read more




Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C

Sat, 22 Apr 2017 11:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Findings Presented at The International Liver Congress™ 2017 Show High Rates of Sustained Virologic Response (SVR12) in Genotype 1 Patients for Whom Direct-Acting Antiviral Therapy Had Previously Failed

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first sustained virologic response1 (SVR) results 12 weeks after completion of therapy (SVR12, considered virologic cure) from C-SURGE , an ongoing, open label Phase 2 clinical trial evaluating MK-3682B [uprifosbuvir (MK-3682)2/grazoprevir3/rusazvir4], the company’s investigational triple-combination therapy in treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection for whom treatm

Language:
English
Contact:

Merck
Media:
Doris Li, 908-740-1903
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Real-World Observational Study in the U.S. Veterans Affairs System Evaluating Use of Merck’s ZEPATIER® (Elbasvir and Grazoprevir) Shows High Sustained Virologic Response Rates in Patients with Chronic Hepatitis C

Fri, 21 Apr 2017 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Study Evaluated VA Population with High Incidence of Co-Morbidities

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the presentation of findings from a retrospective database analysis of patients with chronic hepatitis C virus (HCV) infection who were administered ZEPATIER® in the U.S. Department of Veterans Affairs (VA) healthcare system.

Language:
English
Contact:

Merck & Co., Inc.
Media:
Doris Li, 908-740-1903
or
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Donates $300,000 to Support Neglected Tropical Disease Elimination Efforts in Africa

Thu, 20 Apr 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, announced today a $300,000 cash donation to support non-governmental organization (NGO) partners working to eliminate river blindness (onchocerciasis) and lymphatic filariasis (LF) in Africa.

Language:
English
Contact:

Merck:
Claire Gillespie, 267-305-0932
Jeanine Clemente, 908-740-6268
or
MDP:
Joni Lawrence, 404-687-5610
Yao Sodahlon, 404-371-1460

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Underscores Continued Commitment to Fighting Infectious Diseases With More than 25 Data Presentations at ECCMID 2017

Wed, 19 Apr 2017 12:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that researchers are scheduled to provide more than 25 scientific data presentations on the company’s established and investigational infectious disease medicines at this year’s 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), April 22-25 in Vienna, Austria.

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
or
Robert Consalvo, 908-295-0928
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Togo Becomes First Country in Africa to Validate the Elimination of Lymphatic Filariasis as a Public Health Problem

Tue, 18 Apr 2017 12:00:08 +0000

Dateline City:
LOME, TOGO

LOME, TOGO -- GSK, Merck (known as MSD outside the United States and Canada), and the MECTIZAN® Donation Program (MDP) congratulate President Faure Gnassingbé, the government and the people of Togo for becoming the first country in Africa recognized by the World Health Organization to have eliminated lymphatic filariasis (LF) as a public health problem.

Language:
English

read more




Dr. John H. Noseworthy Nominated to Stand for Election to Merck Board of Directors

Mon, 10 Apr 2017 20:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Dr. John H. Noseworthy, president and chief executive officer of Mayo Clinic, has been nominated to stand for election to the company’s board of directors. The annual election of Dr. Noseworthy and the other directors will take place in connection with Merck’s Annual Meeting of Shareholders on May 23, 2017. With the proposed addition of Dr. Noseworthy, and the planned retirement of C.

Language:
English
Contact:

Merck
Media:
Tracy Ogden, 215-370-5597
or
Investors:
Teri Loxam, 908-740-1986

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin

Fri, 07 Apr 2017 11:30:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter regarding Merck’s Supplemental New Drug Applications for JANUVIA® (sitagliptin), JANUMET® (sitagliptin and metformin HCl) and JANUMET XR® (sitagliptin and metformin HCl extended-release).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Kristen Drake, 908-236-4223
or
Investors:
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Receives 2017 ENERGY STAR Sustained Excellence Award from U. S. Environmental Protection Agency

Thu, 06 Apr 2017 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Company Receives EPA Honor for 12th Consecutive Year

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2017 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued improvement of energy performance and leadership in energy management in both the pharmaceutical and industrial sectors.

Language:
English
Contact:

Merck
Media:
Claire Gillespie, 267-305-0932
or
Investors:
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) and Investigational Combination Therapy MK-3682B for the Treatment of Chronic Hepatitis C Infection at The International Liver Congress™ 2017

Wed, 05 Apr 2017 10:50:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that new data from the company’s chronic hepatitis C virus (HCV) clinical development programs as well as real-world studies on ZEPATIER® (elbasvir and grazoprevir) 50mg/100mg tablets will be presented at the upcoming International Liver Congress™ 2017. Seventeen scientific abstracts will be presented, including oral sessions featuring real-world data on chronic HCV-infected patients treated with ZEPATIER from the U.S.

Language:
English
Contact:

Merck
Media:
Doris Li, 908-740-1903
or
Michael Close, 267-305-1211
or
Investors:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck to Hold First-Quarter 2017 Sales and Earnings Conference Call on May 2

Mon, 03 Apr 2017 10:45:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, will hold its first-quarter 2017 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, May 2. During the call, company executives will provide an overview of Merck’s performance for the quarter and year.

Language:
English
Contact:

Merck
Media:
Claire Gillespie, 267-305-0932
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA® (pembrolizumab)

Fri, 31 Mar 2017 11:00:00 +0000

Dateline City:
WILMINGTON, Del. & KENILWORTH, N.J.

Clinical Program Now Includes Seven Registrational Trials Across Five Tumor Types

WILMINGTON, Del. & KENILWORTH, N.J. Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).

Language:
English

read more




European Medicines Agency’s CHMP Recommends Approval of Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma

Fri, 24 Mar 2017 12:13:00 +0000

Dateline City:
KENILWORTH, N.J.

Recommendation Is for Adult Patients Who Have Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who Are Transplant-Ineligible and Have Failed BV

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma (cHL) who have failed autologous stem cell transplant (ASCT) and brentuximab vedotin (BV), or who are transplant-ineligib

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Kim Hamilton, 908-740-1863
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Animal Health Completes Acquisition of Vallée S.A.

Wed, 22 Mar 2017 20:05:00 +0000

Dateline City:
MADISON, N.J.

Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian Market

MADISON, N.J.--(BUSINESS WIRE)--Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil.

Language:
English
Contact:

For Merck
Media:
Noreen Verbrugge, 973-937-5450
or
Pamela Eisele, 267-305-3558
or
Investors:
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@MerckAH

read more




FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy

Tue, 14 Mar 2017 21:05:00 +0000

Dateline City:
KENILWORTH, N.J.

Only Anti-PD-1 Therapy Approved for the Treatment of Patients with Difficult-to-Treat cHL Regardless of Prior Stem Cell Transplantation or Use of Brentuximab Vedotin

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 (programmed death receptor-1) therapy, for the treatment of adult and pediatric patients with refractory classical Hodgkin lymphoma (cHL), or who have relapsed after three or more prior lines of therapy.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Kim Hamilton, (908) 740-1863
or
Investor:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Provides Update on Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab) in Previously Treated Advanced Microsatellite Instability-High Cancer

Tue, 14 Mar 2017 20:43:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has extended the action date for the supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), the company’s anti-PD-1 therapy, for previously treated patients with advanced microsatellite instability-high (MSI-H) cancer. The company recently submitted additional data and analyses to the FDA related to the pending application.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, (267) 305-3558
or
Kim Hamilton, (908) 740-1863
or
Investor:
Teri Loxam, (908) 740-1986
or
Amy Klug, (908) 740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck and Pfizer Announce U.S. FDA and EMA Filing Acceptances of Three Marketing Applications for Ertugliflozin-Containing Medicines for Adults with Type 2 Diabetes

Mon, 06 Mar 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J. & NEW YORK

Investigational SGLT2 Inhibitor Submitted as Monotherapy and in Fixed-Dose Combinations with JANUVIA ® (sitagliptin) or Metformin

KENILWORTH, N.J. & NEW YORK--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Pfizer Inc. (NYSE:FE), today announced that the U.S.

Language:
English
Contact:

Merck Media:
Doris Li, (908) 246-5701
or
Merck Investor:
Amy Klug, (908) 740-1898
or
Kristen Drake, (908) 236-4223
or
Pfizer Media:
Steve Danehy, (212) 733-1538
or
Pfizer Investor:
Ryan Crowe, (212) 733-8160

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
Ticker:
FE
Exchange:
NYSE
@Merck

read more




Merck Announces Second-Quarter 2017 Dividend

Tue, 28 Feb 2017 18:47:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Board of Directors has declared a quarterly dividend of $0.47 per share of the company’s common stock for the second quarter of 2017. Payment will be made on April 7, 2017 to shareholders of record at the close of business on March 15, 2017.

About Merck

Language:
English
Contact:

Merck
Media:
Lainie Keller, 908-236-5036
or
Claire Gillespie, 267-305-0932
or
Investor:
Teri Loxam, 908-740-1986
or
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Recent Survey Finds Many Adults with Diabetes Unaware of Their Increased Risk for Certain Serious Illnesses

Tue, 28 Feb 2017 18:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Findings Reinforce the Need for Greater Discussions Between Health Care Professionals and Patients to Help Them Understand Their Increased Risk For Pneumococcal Pneumonia/Pneumococcal Disease, Flu and Hepatitis B

KENILWORTH, N.J.--(BUSINESS WIRE)--Many adults with diabetes are unaware of their increased risk for certain serious illnesses, including pneumococcal pneumonia/pneumococcal disease, flu and hepatitis B. This is according to a recent national, online consumer awareness survey sponsored by Merck (NYSE:MRK), known as MSD outside the United States and Canada, and the American Diabetes Association, and conducted by Harris Poll.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 215-652-6059

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Letermovir, an Investigational Antiviral Medicine for Prevention of Cytomegalovirus (CMV) Infection in Bone Marrow Transplant Recipients, Highly Effective Through Week 24 Post-Transplant in Pivotal Phase 3 Study

Sun, 26 Feb 2017 17:30:00 +0000

Dateline City:
KENILWORTH, N.J.

Letermovir Prophylaxis Associated with Lower All-Cause Mortality Through Week 24 Post-Transplant

Company Plans to Submit New Drug Applications for Letermovir in U.S. and EU in 2017

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck & Co., Inc. (NYSE:MRK), known as MSD outside the United States and Canada, today announced results of the pivotal Phase 3 clinical study of letermovir, an investigational antiviral medicine for the prevention of clinically-significant cytomegalovirus (CMV) infection in adult (18 years and older) CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT), also known as bone marrow transplant (BMT).

Language:
English
Contact:

Merck
Media:
Pam Eisele, 267-305-3558
Robert Consalvo, 908-236-1127
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




In First Phase 3 Trial, Merck’s Investigational Inactivated Varicella Zoster Virus Vaccine (V212) Reduced the Incidence of Confirmed Herpes Zoster Cases by an Estimated 64 Percent in Immunocompromised Subjects

Fri, 24 Feb 2017 21:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results for V212, the company’s investigational inactivated varicella zoster virus vaccine (VZV) for the prevention of herpes zoster or HZ, also known as shingles, in immunocompromised patients.

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
or
Skip Irvine, 267-305-0338
or
Investors:
Amy Klug, 908-740-1898
or
Michael DeCarbo, 908-740-1807

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Fight Against Infectious Disease Goes Digital with Launch of ILÚM Health Solutions

Thu, 16 Feb 2017 13:00:00 +0000

Dateline City:
KENILWORTH, N.J.

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the launch of ILÚM Health Solutions, which provides enterprise-wide disease management tools and services to enable improved outcomes for patients with infectious diseases, such as sepsis and pneumonia, while supporting antimicrobial stewardship initiatives. ILÚM operates independently from Merck’s pharmaceutical and vaccine products businesses as part of Merck’s Healthcare Services & Solutions (HSS) group.

Language:
English
Contact:

Media:
Patrick Witmer, 267-305-4910
or
Investors:
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer’s Disease to Stop for Lack of Efficacy

Tue, 14 Feb 2017 22:00:00 +0000

Dateline City:
KENILWORTH, N.J.

APECS Study in People with Prodromal Alzheimer’s Disease to Continue

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 017, also known as the EPOCH study, a Phase 2/3 study evaluating verubecestat, an investigational small molecule inhibitor of the beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), in people with mild-to-moderate Alzheimer’s disease (AD).

Language:
English
Contact:

Merck
Media:
Pamela Eisele, 267-305-3558
Ian McConnell, 908-740-1921
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck’s Doravirine, an Investigational Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) for the Treatment of HIV-1 Infection, Met Primary Efficacy Endpoint in Pivotal Phase 3 Trial

Tue, 14 Feb 2017 21:05:00 +0000

Dateline City:
KENILWORTH, N.J.

Data Presented at CROI Showed Doravirine Was Non-inferior to Ritonavir-boosted Darunavir in Treatment-naïve Adults after 48 weeks of Treatment

KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results of a pivotal Phase 3 clinical trial evaluating the safety and efficacy of doravirine (MK-1439), an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI).

Language:
English
Contact:

Merck
Media:
Doris Li, 908-246-5701
Carmen de Gourville, 267-664-0146
or
Investors:
Teri Loxam, 908-740-1986
Amy Klug, 908-740-1898

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more




Merck Foundation Announces Six Program Grant Recipients for Alliance to Advance Patient-Centered Cancer Care

Thu, 09 Feb 2017 14:00:00 +0000

Dateline City:
KENILWORTH, N.J.

Alliance Aims to Reduce Disparities in Access to High-Quality Cancer Care

KENILWORTH, N.J.--(BUSINESS WIRE)--The Merck Foundation (Foundation), announced today the selection of the six program sites and National Program Office forming the Alliance to Advance Patient-Centered Cancer Care (the Alliance). With $15 million in funding from the Foundation over five years, the Alliance aims to increase timely access to patient-centered cancer care for vulnerable and underserved populations in the United States.

Language:
English
Contact:

For Merck:
Media:
Lainie Keller, 908-236-5036
or
Jeanine Clemente, 908-236-5059

Ticker Slug:
Ticker:
MRK
Exchange:
NYSE
@Merck

read more